Neonatal RAS inhibition changes the phenotype of the developing thick ascending limb of Henle.
D000818:Animals; D000831:Animals, Newborn / Q000502:physiology*; D000918:Antibody Specificity; D000959:Antihypertensive Agents / Q000494:pharmacology; D015153:Blotting, Western; D051546:Cyclooxygenase 2; D005260:Female; D005802:Genes, MHC Class II / Q000235:genetics; D007150:Immunohistochemistry; D007527:Isoenzymes / Q000235:genetics / Q000378:metabolism; D007668:Kidney / Q000187:drug effects / Q000201:enzymology; D008138:Loop of Henle / Q000033:anatomy & histology* / Q000254:growth & development*; D019808:Losartan / Q000494:pharmacology; D010641:Phenotype; D011451:Prostaglandin-Endoperoxide Synthases / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D044140:Receptor, Angiotensin, Type 1 / Q000187:drug effects; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology*; D028021:Sodium-Potassium-Chloride Symporters / Q000378:metabolism
D000959:Antihypertensive Agents; D007527:Isoenzymes; D044140:Receptor, Angiotensin, Type 1; D028021:Sodium-Potassium-Chloride Symporters; D051546:Cyclooxygenase 2; D011451:Prostaglandin-Endoperoxide Synthases; D019808:Losartan